AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26251550 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeinated energy drink (3 mg of caffeine per kg of body mass)
Number of subjects: 13
Study 26251550 — intervention group
Group type: COMPARATOR
Intervention: Placebo drink (no caffeine)
Number of subjects: 13
Study 25280076 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Environment (VE)
Number of subjects: 30
Study 25280076 — intervention group
Group type: COMPARATOR
Intervention: Traditional Paper Floor Plans (FPs)
Number of subjects: 30
Study 22733922 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-rated confidence in assessments by low-volume radiologists
Number of subjects: 119
Study 22733922 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-rated confidence in assessments by high-volume radiologists
Number of subjects: 119
Study 21375190 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic appendectomy (Group B)
Number of subjects: 60
Study 21375190 — intervention group
Group type: COMPARATOR
Intervention: Open appendectomy (Group A)
Number of subjects: 60
Study 18044197 — intervention group
Group type: EXPERIMENTAL
Intervention: Intergenerational programming (IGP) with Montessori-based activities
Number of subjects: 14
Study 18044197 — intervention group
Group type: COMPARATOR
Intervention: Standard activities programming
Number of subjects: 14
Study 16562807 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral nutrition (PN) supplemented with glutamine (0.4 g/kg/day of L-alanine-L-glutamine)
Number of subjects: 49
Study 16562807 — intervention group
Group type: COMPARATOR
Intervention: Standard parenteral nutrition (PN)
Number of subjects: 49
Study 12792701 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg kg‐1 day‐1 ursodeoxycholic acid for three months
Number of subjects: 30
Study 12792701 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 10234869 — intervention group
Group type: EXPERIMENTAL
Intervention: Reflexological treatment for headache
Number of subjects: 220
Study 8704351 — intervention group
Group type: EXPERIMENTAL
Intervention: Patellar ultrasound
Number of subjects: 1401
Study 8704351 — intervention group
Group type: EXPERIMENTAL
Intervention: Forearm densitometry
Number of subjects: 1401
Study 8704351 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 1401
Study 1655987 — intervention group
Group type: EXPERIMENTAL
Intervention: Three or four drugs plus whole-lung irradiation
Number of subjects: 32
Study 1655987 — intervention group
Group type: COMPARATOR
Intervention: Two or three drugs without whole-lung irradiation
Number of subjects: 32
Study 6661381 — intervention group
Group type: EXPERIMENTAL
Intervention: Brotizolam (0.50 mg)
Number of subjects: 0
Study 6661381 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurazepam (30 mg)
Number of subjects: 0
Study 6661381 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30698675 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-treatment genotyping (genotype-guided thiopurine dosing)
Number of subjects: 728
Study 30698675 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (control group)
Number of subjects: 728
Study 27883215 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab monotherapy
Number of subjects: 1078
Study 27883215 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunomodulator combination therapy
Number of subjects: 1078
Study 27883215 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab combination therapy
Number of subjects: 1078
Study 27382454 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferasirox (DFX) - single oral daily dose of 20-40 mg/kg/day
Number of subjects: 60
Study 27382454 — intervention group
Group type: COMPARATOR
Intervention: Deferoxamine (DFO) - 20-50 mg/kg/day via subcutaneous infusion over 8-10 hours, 5 days a week
Number of subjects: 60
Study 25009396 — intervention group
Group type: EXPERIMENTAL
Intervention: Portable endoscopy
Number of subjects: 129
Study 25009396 — intervention group
Group type: COMPARATOR
Intervention: Nasogastric aspiration
Number of subjects: 129
Study 21878578 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 µg/h reservoir with heat
Number of subjects: 5
Study 21878578 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 µg/h matrix with heat
Number of subjects: 5
Study 21878578 — intervention group
Group type: COMPARATOR
Intervention: 50 µg/h reservoir without heat
Number of subjects: 5
Study 21878578 — intervention group
Group type: COMPARATOR
Intervention: 25 µg/h reservoir without heat
Number of subjects: 5
Study 21878578 — intervention group
Group type: COMPARATOR
Intervention: 25 µg/h matrix without heat
Number of subjects: 5
Study 19246572 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 0
Study 17205576 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaloglide
Number of subjects: 30
Study 17205576 — intervention group
Group type: COMPARATOR
Intervention: No postsurgical treatment
Number of subjects: 30
Study 15889357 — intervention group
Group type: EXPERIMENTAL
Intervention: Telavancin (administered intravenously once daily)
Number of subjects: 167
Study 15889357 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (antistaphylococcal penicillin 4 times daily or vancomycin twice daily)
Number of subjects: 167
Study 11281611 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (0.1 mg sc) during exercise
Number of subjects: 6
Study 11281611 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (30 minutes at 60% VO2max)
Number of subjects: 6
Study 11281611 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (0.1 mg sc) after exercise
Number of subjects: 6
Study 11281611 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (0.1 mg sc) without exercise
Number of subjects: 6
Study 11281611 — intervention group
Group type: COMPARATOR
Intervention: Saline during exercise
Number of subjects: 6
Study 11281611 — intervention group
Group type: COMPARATOR
Intervention: No exercise with saline
Number of subjects: 6
Study 9499947 — intervention group
Group type: EXPERIMENTAL
Intervention: Absorbable clip (laproclipR Davis and Geck)
Number of subjects: 100
Study 9499947 — intervention group
Group type: COMPARATOR
Intervention: Metal clips (titan clip ETHICONR)
Number of subjects: 100
Study 7942182 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous injection of interferon and ACNU in addition to radiotherapy (IAR therapy)
Number of subjects: 175
Study 7942182 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant therapy with radiation and chemotherapy
Number of subjects: 175
Study 7942182 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 175
Study 2946583 — intervention group
Group type: COMPARATOR
Intervention: Prednisone 10 mg X 3 daily
Number of subjects: 150
Study 2946583 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA) orally 500 mg daily
Number of subjects: 150
Study 2946583 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA) i.m. 1000 mg daily for 3 weeks followed by 500 mg i.m. weekly
Number of subjects: 150
Study 31856636 — intervention group
Group type: EXPERIMENTAL
Intervention: IDegLira
Number of subjects: 0
Study 31856636 — intervention group
Group type: COMPARATOR
Intervention: IGlar U100
Number of subjects: 0
Study 31856636 — intervention group
Group type: COMPARATOR
Intervention: Basal-bolus therapy
Number of subjects: 0
Study 29500582 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual cognitive‐existential psychotherapy intervention for FCR (6-week duration)
Number of subjects: 25
Study 29500582 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 25
Study 27930553 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid (HA) injection
Number of subjects: 26
Study 27930553 — intervention group
Group type: COMPARATOR
Intervention: 0.9% sodium chloride injection
Number of subjects: 26
Study 27930553 — intervention group
Group type: COMPARATOR
Intervention: Comparison between HA and control group
Number of subjects: 26
Study 24785399 — intervention group
Group type: EXPERIMENTAL
Intervention: Community jury process
Number of subjects: 27
Study 24785399 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 27
Study 23993028 — intervention group
Group type: EXPERIMENTAL
Intervention: Low tidal volume (5 mL/kg + 5 cm H2O positive end-expiratory pressure) preserved ventilation (PV)
Number of subjects: 101
Study 23993028 — intervention group
Group type: COMPARATOR
Intervention: Conventional tidal volume (8 mL/kg) controlled ventilation (CV)
Number of subjects: 101
Study 22010223 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg/kg hydrogen sulfide from wk 0 to 3 and 3 mg/kg from wk 4 to 6
Number of subjects: 384
Study 22010223 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg/kg hydrogen sulfide from wk 0 to 3 and 6 mg/kg from wk 4 to 6
Number of subjects: 384
Study 22010223 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg/kg hydrogen sulfide from wk 0 to 3 and 12 mg/kg from wk 4 to 6
Number of subjects: 384
Study 22010223 — intervention group
Group type: COMPARATOR
Intervention: Control group (no hydrogen sulfide added)
Number of subjects: 384
Study 18312088 — intervention group
Group type: EXPERIMENTAL
Intervention: Coil embolization
Number of subjects: 0
Study 18312088 — intervention group
Group type: COMPARATOR
Intervention: Clip ligation
Number of subjects: 0
Study 16600069 — intervention group
Group type: EXPERIMENTAL
Intervention: Mind Reading software used at home for 10-15 weeks
Number of subjects: 19
Study 16600069 — intervention group
Group type: EXPERIMENTAL
Intervention: Mind Reading software used at home with weekly tutor sessions
Number of subjects: 19
Study 16600069 — intervention group
Group type: COMPARATOR
Intervention: Control group of adults with AS/HFA (n = 22) assessed without intervention
Number of subjects: 19
Study 16600069 — intervention group
Group type: COMPARATOR
Intervention: General population control group (n = 24 in Experiment 1, n = 13 in Experiment 2)
Number of subjects: 19
Study 16600069 — intervention group
Group type: COMPARATOR
Intervention: Social skills training for adults with AS/HFA
Number of subjects: 19
Study 14717315 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia
Number of subjects: 992
Study 14717315 — intervention group
Group type: COMPARATOR
Intervention: Narcotic analgesia
Number of subjects: 992
Study 11023563 — intervention group
Group type: EXPERIMENTAL
Intervention: Second attempt at ERCP
Number of subjects: 562
Study 11023563 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced techniques for cannulation
Number of subjects: 562
Study 11023563 — intervention group
Group type: EXPERIMENTAL
Intervention: ERCP with or without manometry
Number of subjects: 562
Study 11023563 — intervention group
Group type: EXPERIMENTAL
Intervention: ERCP
Number of subjects: 562
Study 19361146 — intervention group
Group type: EXPERIMENTAL
Intervention: Swim training at 60% of maximal heart rate reserve for 45 min per day, 3 days per week for 10 weeks
Number of subjects: 18
Study 19361146 — intervention group
Group type: EXPERIMENTAL
Intervention: Swim training
Number of subjects: 18
Study 19361146 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-exercising)
Number of subjects: 18
Study 19361146 — intervention group
Group type: COMPARATOR
Intervention: Swim training and Control group
Number of subjects: 18
Study 1404051 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous wiring based on the technique described by DePalma
Number of subjects: 0
Study 1404051 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment of manipulation and application of plaster of Paris
Number of subjects: 0
Study 7152079 — intervention group
Group type: EXPERIMENTAL
Intervention: Alclometasone cream 0.05% applied twice a day for 21 days
Number of subjects: 31
Study 7152079 — intervention group
Group type: COMPARATOR
Intervention: Clobetasone butyrate cream 0.5% applied twice a day for 21 days
Number of subjects: 31
Study 31512572 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid supplementation
Number of subjects: 0
Study 31512572 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants' folate status
Number of subjects: 0
Study 31039180 — intervention group
Group type: EXPERIMENTAL
Intervention: Walkasins turned ON
Number of subjects: 31
Study 31039180 — intervention group
Group type: COMPARATOR
Intervention: Walkasins turned OFF
Number of subjects: 31
Study 31039180 — intervention group
Group type: EXPERIMENTAL
Intervention: Walkasins turned OFF-then-ON
Number of subjects: 31
Study 31039180 — intervention group
Group type: COMPARATOR
Intervention: Walkasins turned ON-then-OFF
Number of subjects: 31
Study 31039180 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall assessment
Number of subjects: 31
Study 27677487 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein-Enriched Diet (PED) with protein intake 2.0 g/kg of ideal body weight
Number of subjects: 60
Study 27677487 — intervention group
Group type: COMPARATOR
Intervention: Normal Protein Diet (NPD) with protein intake 1.0 g/kg of ideal body weight
Number of subjects: 60
Study 27233490 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood transfusion
Number of subjects: 415
Study 27233490 — intervention group
Group type: EXPERIMENTAL
Intervention: Anemia (hemoglobin level ≤ 6.0 mmol/L or 9.7 g/dL)
Number of subjects: 415
Study 24392746 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction of labor
Number of subjects: 0
Study 24392746 — intervention group
Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 0
Study 22833684 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary tumour resection plus systemic therapy
Number of subjects: 410
Study 22833684 — intervention group
Group type: COMPARATOR
Intervention: Systemic therapy alone
Number of subjects: 410
Study 18559131 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational programme aimed at discouraging students from drinking sugar-sweetened beverages
Number of subjects: 1140
Study 18559131 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1140
Study 17584200 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed‐wave tissue Doppler imaging (PW‐TDI)
Number of subjects: 32
Study 17584200 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 32
Study 17064199 — intervention group
Group type: EXPERIMENTAL
Intervention: ICA-17043 50 mg
Number of subjects: 28
Study 17064199 — intervention group
Group type: EXPERIMENTAL
Intervention: ICA-17043 100 mg
Number of subjects: 28
Study 17064199 — intervention group
Group type: EXPERIMENTAL
Intervention: ICA-17043 150 mg
Number of subjects: 28
Study 17064199 — intervention group
Group type: EXPERIMENTAL
Intervention: ICA-17043
Number of subjects: 28
Study 17064199 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 12588578 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise and incontinence care provided every 2 hours from 8:00 a.m. to 4:30 p.m. (total of four daily care episodes) 5 days a week for 32 weeks
Number of subjects: 190
Study 12588578 — intervention group
Group type: COMPARATOR
Intervention: Usual care from nursing home staff
Number of subjects: 190
Study 10228457 — intervention group
Group type: EXPERIMENTAL
Intervention: CMV infection
Number of subjects: 192
Study 10228457 — intervention group
Group type: EXPERIMENTAL
Intervention: CMV disease
Number of subjects: 192
Study 10228457 — intervention group
Group type: EXPERIMENTAL
Intervention: Failure of renal graft
Number of subjects: 192
Study 8934060 — intervention group
Group type: EXPERIMENTAL
Intervention: Norplant implants users
Number of subjects: 22
Study 8934060 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 22
Study 1751913 — intervention group
Group type: EXPERIMENTAL
Intervention: Transconjunctival cryopexy of the peripheral retina and vitreous base
Number of subjects: 16
Study 1751913 — intervention group
Group type: COMPARATOR
Intervention: Systemic and periocular steroid therapy
Number of subjects: 16
Study 7042090 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy with MOPP and ABDV given in alternating months; Radiation therapy (RT) (2000 rad in 2 weeks) during Month 5
Number of subjects: 91
Study 26840438 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression Garments (CGs)
Number of subjects: 18
Study 26840438 — intervention group
Group type: COMPARATOR
Intervention: Regular gym shorts
Number of subjects: 18
Study 28821315 — intervention group
Group type: EXPERIMENTAL
Intervention: Starch-entrapped microspheres (SM) 9 or 12 g
Number of subjects: 43
Study 28821315 — intervention group
Group type: COMPARATOR
Intervention: Psyllium (12 g)
Number of subjects: 43
Study 28821315 — intervention group
Group type: EXPERIMENTAL
Intervention: Both SM and psyllium
Number of subjects: 43
Study 26357934 — intervention group
Group type: EXPERIMENTAL
Intervention: Group S (supine position immediately after injection)
Number of subjects: 30
Study 26357934 — intervention group
Group type: EXPERIMENTAL
Intervention: Group L5 (lateral for 5 min then supine)
Number of subjects: 30
Study 26357934 — intervention group
Group type: EXPERIMENTAL
Intervention: Group L10 (lateral for 10 min then supine)
Number of subjects: 30
Study 24083593 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment Region (TR)
Number of subjects: 200000
Study 24083593 — intervention group
Group type: COMPARATOR
Intervention: Usual Care Region (UCR)
Number of subjects: 200000
Study 22122001 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye Movement Desensitization and Reprocessing (EMDR)
Number of subjects: 90
Study 22122001 — intervention group
Group type: COMPARATOR
Intervention: Citalopram
Number of subjects: 90
Study 18941065 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic contrast-enhanced MRI before and after two cycles of chemotherapy
Number of subjects: 54
Study 18941065 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic contrast-enhanced MRI
Number of subjects: 54
Study 15983964 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer mentoring
Number of subjects: 203
Study 15983964 — intervention group
Group type: COMPARATOR
Intervention: Standard printed material
Number of subjects: 203
Study 12508078 — intervention group
Group type: EXPERIMENTAL
Intervention: High amino acid intake (HAA) at 3 g.kg(‐1).d(‐1)
Number of subjects: 28
Study 10624193 — intervention group
Group type: EXPERIMENTAL
Intervention: 3M Tegasorb dressing
Number of subjects: 90
Study 10624193 — intervention group
Group type: COMPARATOR
Intervention: ConvaTec's Granuflex (E)
Number of subjects: 90
Study 8558194 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorouracil (5FU) based chemotherapy: 200 mg/m2/d for 3 weeks with leucovorin 20 mg/m2/w, plus Cisplatin 100 mg/m2 on day 1
Number of subjects: 65
Study 8558194 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorouracil (5FU) based chemotherapy
Number of subjects: 65
Study 1859765 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 0.2 mg
Number of subjects: 80
Study 1859765 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 0.3 mg
Number of subjects: 80
Study 1859765 — intervention group
Group type: COMPARATOR
Intervention: Temazepam 20 mg
Number of subjects: 80
Study 1859765 — intervention group
Group type: COMPARATOR
Intervention: Clonidine 0.1 mg
Number of subjects: 80
Study 6630314 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral papaverine (600 mg)
Number of subjects: 13
Study 6630314 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous papaverine (100 mg)
Number of subjects: 13
Study 6630314 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 30142023 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep condition
Number of subjects: 0
Study 30142023 — intervention group
Group type: COMPARATOR
Intervention: Wake condition
Number of subjects: 0
Study 28833192 — intervention group
Group type: EXPERIMENTAL
Intervention: Agomelatine
Number of subjects: 0
Study 28833192 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine
Number of subjects: 0
Study 25909546 — intervention group
Group type: EXPERIMENTAL
Intervention: Total myocardial revascularization
Number of subjects: 131
Study 25909546 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective revascularization
Number of subjects: 131
Study 25909546 — intervention group
Group type: EXPERIMENTAL
Intervention: Elimination of ischemia in hibernating myocardium
Number of subjects: 131
Study 23143142 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT), administered two times per week for 4 weeks, n = 12
Number of subjects: 21
Study 23143142 — intervention group
Group type: COMPARATOR
Intervention: Placebo group, n = 9
Number of subjects: 21
Study 22947909 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin and antihistamines
Number of subjects: 50
Study 22947909 — intervention group
Group type: COMPARATOR
Intervention: Placebo and antihistamines (Control group)
Number of subjects: 50
Study 18926645 — intervention group
Group type: EXPERIMENTAL
Intervention: D-amphetamine (0, 15, and 30 mg/day)
Number of subjects: 7
Study 18926645 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine (4, 30, 60 mg, i.n.)
Number of subjects: 7
Study 18926645 — intervention group
Group type: COMPARATOR
Intervention: D-amphetamine (30 mg/day)
Number of subjects: 7
Study 18926645 — intervention group
Group type: COMPARATOR
Intervention: D-amphetamine (0 mg/day)
Number of subjects: 7
Study 17698275 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine (up to 400 mg/day)
Number of subjects: 15
Study 17698275 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 17698275 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 15
Study 15010743 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin (not specified dosage or duration)
Number of subjects: 403
Study 15010743 — intervention group
Group type: COMPARATOR
Intervention: Not anticoagulated
Number of subjects: 403
Study 15010743 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinus rhythm maintenance
Number of subjects: 403
Study 11223113 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychogeriatric consultation
Number of subjects: 0
Study 11223113 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study 9203245 — intervention group
Group type: EXPERIMENTAL
Intervention: Remacemide hydrochloride (300 mg single dose, 150 mg or 300 mg twice daily for 14 days)
Number of subjects: 17
Study 9203245 — intervention group
Group type: EXPERIMENTAL
Intervention: Remacemide hydrochloride (150 mg twice daily)
Number of subjects: 17
Study 9203245 — intervention group
Group type: EXPERIMENTAL
Intervention: Remacemide hydrochloride (300 mg twice daily)
Number of subjects: 17